严重对乙酰氨基酚中毒的代谢与线粒体治疗:系统综述
本文为系统综述,检索至2020年6月,纳入89项研究,评估西咪替丁、甲吡唑和calmangafodipir治疗对乙酰氨基酚中毒的实验与临床数据。西咪替丁有良好动物证据抑制CYP 2E1,但两项对比试验未发现获益,且重症患者少;甲吡唑有良好动物证据抑制CYP 2E1,但无对比试验,病例报告因均合用乙酰半胱氨酸而无法定论,辅助治疗获益未证实;calmangafodipir模拟超氧化物歧化酶,已完成I/II期安全性试验,III期疗效研究正在筹划。结论:绝大多数急性对乙酰氨基酚过量患者单用乙酰半胱氨酸结局良好,西咪替丁和甲吡唑证据不足以推荐作为主要或辅助治疗,calmangafodipir仍在研究中。
要点
- 绝大多数急性对乙酰氨基酚过量患者单用乙酰半胱氨酸即可获得良好结局。
- 西咪替丁有良好动物证据抑制CYP 2E1,但两项对比试验未发现对乙酰氨基酚中毒获益,且重症患者少。
- 甲吡唑有良好动物证据抑制CYP 2E1,但无急性对乙酰氨基酚中毒的对比试验,病例报告因均合用乙酰半胱氨酸而无法定论,辅助治疗获益未证实。
- calmangafodipir模拟超氧化物歧化酶,已完成急性对乙酰氨基酚过量人体I/II期安全性试验,III期疗效研究正在筹划。
- 证据不足以推荐西咪替丁或甲吡唑作为对乙酰氨基酚中毒的主要或辅助治疗。
适用人群与场景
- 急性对乙酰氨基酚过量患者,包括摄入极大剂量或就诊较晚、在应用乙酰半胱氨酸后仍发生急性肝衰竭并出现提示线粒体毒性的代谢性酸中毒者。
红旗征与不能漏的情况
- 摄入极大剂量对乙酰氨基酚或就诊较晚的患者,即使应用乙酰半胱氨酸仍可能发生急性肝衰竭。
- 部分患者出现代谢性酸中毒,提示线粒体毒性。
研究设计与关键结果
- 系统综述检索Ovid Medline 1946-2020、Embase 1947-2020、Scopus 2004-2020、Cochrane系统评价数据库、Cochrane对照试验中心注册库和clinicaltrials.gov 1997-2020,最终纳入89项研究。
- 西咪替丁:有良好动物证据显示其阻断CYP 2E1,可能抑制对乙酰氨基酚毒性代谢;早期病例报告关于人体获益无定论;两项对比试验未发现西咪替丁在对乙酰氨基酚中毒中的获益,但重症中毒患者少。
- 甲吡唑:有良好动物证据显示其阻断CYP 2E1,可能抑制对乙酰氨基酚毒性代谢;无急性对乙酰氨基酚中毒的对比试验;病例报告因所有病例均合用乙酰半胱氨酸等多种干预而无法定论;作为辅助治疗的获益未证实。
- calmangafodipir:模拟超氧化物歧化酶,因超氧自由基形成似乎可解释极大剂量对乙酰氨基酚过量部分线粒体毒性,已成为严重对乙酰氨基酚毒性的潜在治疗;已在急性对乙酰氨基酚过量人体中完成I/II期安全性试验;III期疗效研究正在筹划。
- 结论:绝大多数急性对乙酰氨基酚过量患者单用乙酰半胱氨酸结局良好;西咪替丁和甲吡唑虽在动物中抑制CYP 2E1,但证据不足以推荐其作为对乙酰氨基酚中毒的主要或辅助治疗;calmangafodipir仍在研究中。
证据类型、等级与局限
- 证据类型:系统综述,检索多项数据库并注册PROSPERO,纳入基础动物研究和所有可获得的人体研究类型。
- 西咪替丁:有良好动物证据,但两项对比试验未发现获益,且重症中毒患者少。
- 甲吡唑:有良好动物证据,但无对比试验,病例报告因均合用乙酰半胱氨酸而无法定论,辅助治疗获益未证实。
- calmangafodipir:已完成I/II期安全性试验,III期疗效研究正在筹划,仍为研究性治疗。
- 局限:原文未报告局限性
对床旁实践的改变
- 绝大多数急性对乙酰氨基酚过量患者单用乙酰半胱氨酸即可获得良好结局。
- 证据不足以推荐西咪替丁作为对乙酰氨基酚中毒的主要或辅助治疗。
- 证据不足以推荐甲吡唑作为对乙酰氨基酚中毒的主要或辅助治疗。
- calmangafodipir仍为研究性治疗,尚未进入常规临床使用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Paracetamol (acetaminophen) remains a leading cause of poisoning in Europe, North America, and Australia. For over four decades, acetylcysteine has been the antidote of choice. However, despite the use of acetylcysteine, some patients who ingest very large doses of paracetamol or who reach hospital late in the course of their poisoning, develop acute liver failure. Some will develop metabolic acidosis indicating mitochondrial toxicity.
OBJECTIVE: We review the experimental and clinical data reported with the use of cimetidine, fomepizole, and calmangafodipir in the treatment of paracetamol toxicity to determine if these treatments alone or in combination with acetylcysteine might be of benefit.
METHODS: We searched Ovid Medline 1946-2020, Embase 1947-2020, Scopus 2004-2020, Cochrane Databases of Systematic Reviews (CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), and clinicaltrials.gov 1997-2020 for records including the concepts of paracetamol poisoning and cimetidine, fomepizole, calmangafodipir, and acetylcysteine. We included basic science studies in animals and all available study types in humans. We reviewed the reference lists of included articles to search for references missed in the original search. We registered the protocol in PROSPERO.
RESULTS: We completed all search strategies on 20 August 2019, 27 January 2020, and 15 June 2020. These produced 6,826 citations. We identified and deleted 2,843 duplicate resulting in a total of 3,856 unique citations. After applying inclusion and exclusion criteria, 89 studies remained. The largest numbers of studies described the past use of cimetidine, and the more recent use of fomepizole.Cimetidine: There is good animal evidence that cimetidine blocks CYP 2E1 with the potential to inhibit the toxic metabolism of paracetamol. Early case reports were inconclusive regarding the benefit to humans in paracetamol poisoning. Two comparative trials found no benefit of cimetidine in paracetamol poisoning, but few patients had severe poisoning.Fomepizole: There is good animal evidence that fomepizole blocks CYP 2E1 with the potential to inhibit the toxic metabolism of paracetamol. There are no comparative trials of fomepizole for acute paracetamol poisoning. Case reports are inconclusive due to multiple other interventions including the use of acetylcysteine in all cases. The benefit of fomepizole as adjunct treatment has not been demonstrated.Calmangafodipir: Calmangafodipir, a drug mimicking superoxide dismutase, has emerged as a potential treatment for severe paracetamol toxicity because the formation of superoxide free radicals appears to explain part of the mitochondrial toxicity of extremely large paracetamol overdoses. Calmangafodipir has reached Phase I/II trial of safety in humans with acute paracetamol overdose. Planning for a Phase III study of efficacy is currently underway.
CONCLUSIONS: The vast majority of patients with acute paracetamol overdose enjoy excellent outcomes with acetylcysteine alone. Although cimetidine and fomepizole inhibit CYP 2E1 in animals, there is insufficient evidence to recommend their use either as a primary treatment or adjunct therapy in paracetamol poisoning. Calmangafodipir remains investigational.
参考来源
- Mullins ME, Yeager LH, Freeman WE, et al. Metabolic and mitochondrial treatments for severe paracetamol poisoning: a systematic review. Clin Toxicol (Phila). 2020. PMID: 32762579. doi:10.1080/15563650.2020.1798979
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。